Cyclica announced a multi-phase collaboration with Eurofarma to advance drug discovery programs by driving insights into small molecule polypharmacology.
Nanology Labs Wins Ontario Brain Institute Award
Therapure Biomanufacturing Announces FDA Approval for Manufacturing of Insmed’s ARIKAYCE®
Therapure Biomanufacturing announced approval for the manufacturing of partner Insmed’s ARIKAYCE® at its Mississauga facility by the U.S. FDA. ARIKAYCE is the first and only treatment approved by the FDA specifically for patients with Mycobacterium avium complex lung disease, a chronic and debilitating condition that can significantly increase patient morbidity and mortality.
Nobel Prize in Physiology or Medicine Recognizes Breakthrough Cancer Research
The 2018 Nobel Prize in Physiology or Medicine was awarded jointly to James P. Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation.”
Register Now for HealthTO October Edition, Oct 10
Apply now for H2i's Pitch Perfect Competition
Flosonics Medical Accepted into Lazaridis Scale-Up Program
Impact Centre Releases Report "The Land of Stranded Pilots"
BIOTECanada and Deloitte Release Results of Biotechnology Industry Data Survey
On Now: Global Biotech Week, Sept 24-30
Register Now for Upcoming Medventions Lectures
VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards
MaRS and University of Toronto Announce New Waterfront Tech Hub
Register Now for the Medicine by Design Symposium, Dec 4
Canada's Economic Strategy Tables Release Health and Biosciences Report
The report entitled “The Innovation and Competitiveness Imperative: Seizing Opportunities for Growth”, contains recommendations from six sectors with high growth potential, including the health and biosciences sector. The report outlined the roadmap to doubling the size of the health and biosciences sector and becoming a top-three global hub.
Elucid Labs Wins ElevateR Pitch People’s Choice
VBI Vaccines Announces Second Positive DSMB Review
VBI Vaccines, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced that the independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent GBM.
ManagingLife Announces Collaboration with Sun Life
ProteinQure Announces Collaboration with Fujitsu Labs
CABHI announces new Mentorship, Capital and Continuation Program
The Centre for Aging + Brain Health Innovation (CABHI), led by Baycrest and in partnership with National Bank, announced the launch of a new Mentorship, Capital and Continuation Program (MC2). MC2 will accelerate market-ready healthcare innovations for the aging population from bench to bedside more quickly and efficiently.